Skip to main content

IsoPlexis Corporation (ISO)

NASDAQ: ISO · IEX Real-Time Price · USD
8.59 0.00 (0.00%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap334.62M
Revenue (ttm)12.01M
Net Income (ttm)-32.97M
Shares Out38.95M
EPS (ttm)-0.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume219,278
Open8.13
Previous Close8.59
Day's Range7.40 - 8.78
52-Week Range7.40 - 16.95
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateNov 10, 2021

About ISO

IsoPlexis is enabling deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine. Our single cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a more complete view of protein function at an individual cellular level. Since our commercial launch in June of 2018, our platform has been adopted by the top 15 global biopharmaceutical companies by revenue and nearly half of the comprehensive can...

IndustryMedical Devices
IPO DateOct 8, 2021
CEOSean Mackay
Employees232
Stock ExchangeNASDAQ
Ticker SymbolISO
Full Company Profile

Financial Performance

Financial Statements

News

IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and ...

1 week ago - PRNewsWire

IsoPlexis to Participate in the Evercore ISI HealthCONx Conference

BRANFORD, Conn., Nov. 24, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today announced the company will be participating virtually in the up...

2 weeks ago - PRNewsWire

IsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine Publications

BRANFORD, Conn., Nov. 18, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the publication of two high-impact clinical research ...

2 weeks ago - PRNewsWire

IsoPlexis Bolsters Its Global Operational and Product Support Leadership

BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company.

3 weeks ago - PRNewsWire

IsoPlexis Reports Third Quarter 2021 Financial Results

BRANFORD, Conn., Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, ...

4 weeks ago - PRNewsWire

IsoPlexis to Present Data at SITC 2021 Connecting Genetic Drivers to Functional Proteomics

BRANFORD, Conn., Nov. 5, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced that data generated on its IsoLight® and IsoSpark® Pla...

1 month ago - PRNewsWire

IsoPlexis to Report Third Quarter Financial Results on November 10, 2021

BRANFORD, Conn., Oct. 26, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), a leader in functional single-cell proteomics, today announced it will report financial results for the third quarter ...

1 month ago - PRNewsWire

IsoPlexis Announces Closing of Public Offering

BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000...

1 month ago - PRNewsWire

IsoPlexis, a company uncovering a ‘new layer' of cell data, aims for $125M in market debut

Shares of IsoPlexis, a company creating tools to zoom in on the flurry of protein activity surrounding a single cell, began trading on Friday. The company aims to raise about $125 million with the IPO, ...

2 months ago - TechCrunch

IsoPlexis Announces Pricing of Initial Public Offering

BRANFORD, Conn., Oct. 7, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the pricing of its initial public offering of 8,333,000 ...

2 months ago - PRNewsWire